23 results
P
24,913 participants
I/C
NA reduction, smoking relapse
O
weakly linked
P
adult
I/C
nucleoside analogues (NA), placebo or no intervention
O
virological cure, elimination of acute infection, mortality, and serious adverse events
P
women with ovarian cancer
I/C
metformin, statins, beta-blockers, aspirin, non-aspirin non-steroidal anti-inflammatory drugs (NA-NSAIDs), users vs. non-users
O
ovarian cancer survival
P
Hepatitis B virus (HBV) chronic infection patients
I/C
Nucleos(t)ide analogues (NA), plasma exchange, rituximab
O
suppression of HBV replication, clinical response, severe or life-threatening cases
P
Li QL, Yao MF, Cao RY, Zhao K, Wang XD
I/C
short dental implants, splinted and nonsplinted prostheses
O
survival rates
P
IHCs
I/C
Pegylated interferon (Peg-IFN) treatment, Control group (including nucleos(t)ide analogue (NA) treatment or no treatment)
O
HBsAg clearance rate, conversion rate
P
765 participants
I/C
infiltrating nasal packing with local anesthetics, placebo packing
O
pain reduction, anxiety reduction
P
morbid obesity patients
I/C
laparoscopic sleeve gastrectomy (LSG), Roux-en-Y laparoscopic gastric bypass (RYLGB)
O
weight loss, resolution of comorbidities, postoperative complications, operative time, hospital stay, and improvement in quality of life
P
health professionals
I/C
systematic review and meta-analysis of studies published in any language in 2020, men vs women, nurses vs physicians, front line vs non-front line workers, infected vs non-infected with coronavirus, chronic diseases vs no chronic diseases
O
prevalence of anxiety
P
care dyads, person with ostomy, caregiver
I/C
permanent discharge ostomy, no ostomy
O
rejection of bodily changes and sexual dysfunction, assertive and effective family care